Lesson plan
DOPF
DOPF, also known as 2,5-dimethoxy-4-(3-fluoropropyl)amphetamine, is a designer drug from the amphetamine and DOx families. It was first synthesised by Alexander Shulgin and David Nichols in 1989 but was never published at the time, and was finally disclosed in Daniel Trachsel's review of the field in 2013. It has a binding affinity (K i ) of 9 nM at the serotonin receptor 5-HT 2A but is not known to have been tested in humans. DOPF is a controlled substance in Canada under phenethylamine blanket-ban language.
Article summary
DOPF, also known as 2,5-dimethoxy-4-(3-fluoropropyl)amphetamine, is a designer drug from the amphetamine and DOx families. It was first synthesised by Alexander Shulgin and David Nichols in 1989 but was never published at the time, and was finally disclosed in Daniel Trachsel's review of the field in 2013. It has a binding affinity (K i ) of 9 nM at the serotonin receptor 5-HT 2A but is not known to have been tested in humans. DOPF is a controlled substance in Canada under phenethylamine blanket-ban language.
Key claims
- publication date: 2013 — source: Wikipedia · confidence 0.95
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- The record states that the publication date is "2013". What evidence would count against this claim?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
- Wikipedia https://en.wikipedia.org/w/index.php?oldid=1377228809
Key claims and bibliography are generated from the same tracked claims and sources as the article page.